Choose your language
Japanese
Korean
English

目录下载(PDF)




产业会议汇总历

TIDES: Oligonucleotide and Peptide® Research, Technology and Product Development

CSS

The Industry's Only Event for Full Coverage of the Oligonucleotide and Peptide Markets

2012年5月20-23日· Mandalay Bay Resort & Casino · Las Vegas, NV

Event Overview

Event Overview

TIDES 2012
(寡核苷酸以及肽的研究、技术、产品开发相关学会)
2012年5月20-23日 | Las Vegas, USA

寡核苷酸与肽的制造技术以及产品开发

CMC的各课题、初期制剂开发、针对药物输送的代替投药技术相关案例研究

关于让将来的计画立案充满活力的基础会议

  • 近年制药业界的变化与寡核苷酸疗法进歩相关的光明前景
  • 对于「RNAi干扰」建设动作不断的中国的RNAi(RNA干渉)相关的提议分析
  • 以肽激素为基础的最高水准治疗法开发为目标的最新技术平台活用战略
  • 以发现肽疗法为目的的基因密码重新编程相关的报告
  • Novartis、Ironwood、Affymax、Regado、Alnylam、Dynavax、Excaliard研究员所进行的报告中、最有希望的肽疗法与寡核苷酸疗法的临床开发相关的最新情报
  • Pfizer、Prosensa、Emergent BioSolutions、Bachem、RAPID Laboratories研究员预定有CMC课题与对策相关的案例研究、可以成为评断自家开发作业时的基准
  • lnylam、TransDerm、Dynavax、Pfizer、MannKind Corporation、Amunix研究员将报告患者负担较少的药物输送相关讯息-有助于市场占有率扩大之外、也可以更了解各种药物输送系统的相关制造上课题
  • 藉由参加不纯物的分析、药物输送用的代替路径、共役、由设计提升品质、剂形变更用的战略、肽组换与合成的相关重要问题之战略性立场讨论的Strategy Discussion Forum、可以更积极的关怀业界的发展

寡核苷酸治疗药的创药

加速前临床开发与临床开发的药剂般特性之改善

  • 寡核苷酸的输送机制以及标的化
  • 改善药剂般的特性用的化学修饰
  • 各种前临床研究以及临床研究中所得到的新数据
  • miRNA阻碍剂与非编码RNA
  • 反义、siRNA、LNA、适体、免疫修饰
  • 改善组织内作用以及细胞作用的战略

肽创药与开发

以治疗法的开发为目的的细胞内药、新的立足点、做为改良分子的肽之开发

  • 伴随内因性机能活性的CPP
  • 新的肽立足点与构造
  • 肽的独创的性工程、设计、最适化
  • 细胞透过性肽与膜透过性肽
  • 制作药剂般的肽与改良肽的新手法
  • 肽所改变的新标的与疾病机制

分子诊断用的核酸技术

透过法规、事业、技术面的最新战略的产品开发之加速化

  • 诊断业界中的智能财产面的课题
  • Canon投入的基因监测平台
  • 以次世代定序与试料调制为首的新技术最新动向
  • Roche Molecular Systems的伴随诊断药之共同开发
  • Abbott Molecular推进的个别化医疗构想最新动向
  • Roche与Merck开始开发的超高速液体色谱(UHPLC)技术最新动向

Here's what other attendees said about TIDES

"I've looked over the entire agenda and the TIDES 2012 seems like it will be one of the best, if not THE best, meeting I'll attend in 2012." - Richard A. Montagna, Ph.D., Senior Vice President for Corporate Business Development & Scientific Affairs, Rheonix, Inc.

"I have never heard so many good lectures in so little time. Excellent program! Would go again next year." - Peter Timmerman, Chief Technology Officer, Pepscan Therapeutics

"TIDES 2011 was a very productive conference. I had lots of good meetings, with many types of companies. The marriage of the conferences on discovery and manufacturing will make this event a must be for people interested in the TIDES, particularly the oligonucleoTIDES field." - Sven Klussmann, Ph.D., Chief Scientific Officer, NOXXON Pharma AG, Germany

"The TIDES 2011 Conference was a very well organised event. I enjoyed the conference and found it a very good networking platform with vendors and other attendees from various pharmaceutical companies. I shared my latest data in a poster presentation which sparked off some interesting conversations, and I will be applying my learning's from the conference in my day to day investigations." - Nainesh Patel, Senior Scientist, GlaxoSmithKline, UK

"TIDES is an excellent meeting to catch up on the latest efforts in industry on peptide therapeutics and technologies." - Suresh M. Pitram, Senior Research Investigator, Integrated Diagnostics

"Excellent oligonucleotide chemistry, discovery and optimization…" - Steve Shrewsbury, Chief Medical Officer, AVI Biopharma